EUCTR2004-002243-27-AT进行中（未招募）不适用
Vascular effects of peroxisome proliferator–activated receptor gamma stimulation with rosiglitazone during exogenousely elevated free fatty acid concentrations in healthy volunteers - Rosiglitazone and FFA
Clinical Pharmacology0 个研究点目标入组 16 人开始时间: 2004年10月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- male nonsmokers
- •- age: 18 to 35 years
- •- Body mass index between 15th and 85th percentile
- •- Normal findings in medical history, physical and laboratory examinations including OGTT unless the investigator considers an abnormality to be clinically irrelevant
- •- written informed consent
- •- Normal ophthalmic findings, ametropy < 3 Dpt.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceeding the study
- •- Evidence of hypertension, pathologic hyperglycemia, hyperlipidemia
- •- Treatment in the previous 3 weeks with any drug
- •- Symptoms of a clinically relevant illness in the 3 weeks before the first study day
- •- History or presence of gastrointestinal, liver or kidney disease, or other conditions known to interfere with distribution, metabolism or excretion of study drugs
- •- Blood donation during the previous 3 weeks
- •- History of hypersensitivity to the trial drug or to drugs with a similar chemical structure
研究者
相似试验
进行中（未招募）
不适用
The effect of peroxisome proliferator activator receptor ? agonist pre-treatment on pegylated interferon-a2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - - HEPAR studyChronic hepatitis C infectionMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2007-007075-16-NLVU university medical center50
撤回
不适用
The effect of peroxisome proliferator activator receptor * agonist pre-treatment on pegylated interferon-*2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trialViral liver disease1001965410047438Hepatitis CNL-OMON31787Vrije Universiteit Medisch Centrum50
进行中（未招募）
不适用
Effects of the activation of PPARs in the orphan hepatic disease primary biliary cirrhosisp to 67% of PBC patients have an incomplete biochemical response to UDCA and remain at increased risk for progression to cirrhosis and liver-related death. In this study we will prospectively examine the therapeutic effects of bezafibrate (a pan-agonist activating PPARalpha/delta/gamma) in patients with early-stage PBC with a specific focus on improvement of liver functions, inflammation, lipid profile, oxidative status and endothelial function.EUCTR2011-004681-15-ATMedizinische Universität Graz
已完成
不适用
Can the use of the Peroxisome Proliferator-Activated Receptor (PPAR)-gamma agonist rosiglitazone reverse the abnormal distribution of fat, as well as disturbances in glucose and lipid metabolism in Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndrome?Human Immunodeficiency Virus (HIV)-associated lipodystrophy syndromeInfections and InfestationsHuman Immunodeficiency VirusISRCTN78808170Academic Medical Centre (AMC) (The Netherlands)15
进行中（未招募）
1 期
The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer - PPAREUCTR2006-001398-44-GBBarts and The London NHS Trust49